Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy.

Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA.

Pancreas. 2008 Oct;37(3):269-74. doi: 10.1097/MPA.0b013e31816d8185.

PMID:
18815548
2.

[Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy].

An X, Li YH, Lin XB, Wang FH, Feng F, Xu RH, Jiang WQ, He YJ.

Ai Zheng. 2009 Mar;28(3):286-91.

PMID:
19619444
3.

Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.

Bauer TM, El-Rayes BF, Li X, Hammad N, Philip PA, Shields AF, Zalupski MM, Bekaii-Saab T.

Cancer. 2013 Jan 15;119(2):285-92. doi: 10.1002/cncr.27734. Epub 2012 Jul 11.

4.

Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.

Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA.

Br J Cancer. 2005 Jul 25;93(2):195-9.

5.

CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy.

Hammad N, Heilbrun LK, Philip PA, Shields AF, Zalupski MM, Venkatramanamoorthy R, El-Rayes BF.

Asia Pac J Clin Oncol. 2010 Jun;6(2):98-105. doi: 10.1111/j.1743-7563.2010.01290.x.

6.

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

Chiorean EG, Von Hoff DD, Reni M, Arena FP, Infante JR, Bathini VG, Wood TE, Mainwaring PN, Muldoon RT, Clingan PR, Kunzmann V, Ramanathan RK, Tabernero J, Goldstein D, McGovern D, Lu B, Ko A.

Ann Oncol. 2016 Apr;27(4):654-60. doi: 10.1093/annonc/mdw006. Epub 2016 Jan 22.

7.

Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer.

Rocha Lima CM, Savarese D, Bruckner H, Dudek A, Eckardt J, Hainsworth J, Yunus F, Lester E, Miller W, Saville W, Elfring GL, Locker PK, Compton LD, Miller LL, Green MR.

J Clin Oncol. 2002 Mar 1;20(5):1182-91.

PMID:
11870159
8.

CA19-9: a pedictor of response in pancreatic cancer treated with gemcitabine and cisplatin.

Heinemann V, Schermuly MM, Stieber P, Schulz L, J├╝ngst D, Wilkowski R, Schalhorn A.

Anticancer Res. 1999 Jul-Aug;19(4A):2433-5.

PMID:
10470171
9.

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.

Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, Scheithauer W, Siena S, Tabernero J, Teixeira L, Tortora G, Van Laethem JL, Young R, Penenberg DN, Lu B, Romano A, Von Hoff DD.

J Natl Cancer Inst. 2015 Jan 31;107(2). pii: dju413. doi: 10.1093/jnci/dju413. Print 2015 Feb.

PMID:
25638248
10.

Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy.

Tas F, Karabulut S, Ciftci R, Sen F, Sakar B, Disci R, Duranyildiz D.

Cancer Chemother Pharmacol. 2014 Jun;73(6):1163-71. doi: 10.1007/s00280-014-2450-8. Epub 2014 Mar 20.

PMID:
24647734
11.

Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study.

Vainshtein JM, Schipper M, Zalupski MM, Lawrence TS, Abrams R, Francis IR, Khan G, Leslie W, Ben-Josef E.

Int J Radiat Oncol Biol Phys. 2013 May 1;86(1):96-101. doi: 10.1016/j.ijrobp.2012.11.020. Epub 2012 Dec 19.

12.

Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels.

Abrams RA, Grochow LB, Chakravarthy A, Sohn TA, Zahurak ML, Haulk TL, Ord S, Hruban RH, Lillemoe KD, Pitt HA, Cameron JL, Yeo CJ.

Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1039-46.

PMID:
10421536
13.

First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.

Vaccaro V, Bria E, Sperduti I, Gelibter A, Moscetti L, Mansueto G, Ruggeri EM, Gamucci T, Cognetti F, Milella M.

World J Gastroenterol. 2013 Jul 28;19(28):4511-9. doi: 10.3748/wjg.v19.i28.4511.

14.

Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.

Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA.

J Clin Oncol. 2006 Jan 20;24(3):379-85. Epub 2005 Dec 12.

PMID:
16344320
15.

Gemcitabine-Based Regional Intra-Arterial Infusion Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma.

Liu X, Yang X, Zhou G, Chen Y, Li C, Wang X.

Medicine (Baltimore). 2016 Mar;95(11):e3098. doi: 10.1097/MD.0000000000003098.

16.

A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.

Ko AH, Truong TG, Kantoff E, Jones KA, Dito E, Ong A, Tempero MA.

Cancer Chemother Pharmacol. 2012 Dec;70(6):875-81. doi: 10.1007/s00280-012-1979-7. Epub 2012 Sep 28.

PMID:
23053263
17.

Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.

Saif MW, Syrigos K, Penney R, Kaley K.

Anticancer Res. 2010 Jul;30(7):2905-9.

PMID:
20683031
18.

Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis.

Goulart BH, Clark JW, Lauwers GY, Ryan DP, Grenon N, Muzikansky A, Zhu AX.

J Hematol Oncol. 2009 Mar 16;2:13. doi: 10.1186/1756-8722-2-13.

19.

Early decrement of serum carbohydrate antigen 19-9 predicts favorable outcome in advanced pancreatic cancer.

Chung KH, Ryu JK, Lee BS, Jang DK, Lee SH, Kim YT.

J Gastroenterol Hepatol. 2016 Feb;31(2):506-12. doi: 10.1111/jgh.13075.

PMID:
26250642
20.

A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma.

Park BB, Park JO, Lee HR, Lee J, Choi DW, Choi SH, Heo JS, Lee JK, Lee KT, Lim DH, Park YS, Lim HY, Kang WK, Park K.

Cancer Chemother Pharmacol. 2007 Sep;60(4):489-94. Epub 2007 Mar 30.

PMID:
17396266

Supplemental Content

Support Center